Survival with untreated lung cancer depends heavily on how advanced the disease is at diagnosis, but the numbers are sobering across the board. For the most common type, non-small cell lung cancer (NSCLC), a large systematic review pooling data from multiple study designs found an average survival without any anticancer treatment of roughly seven months.1BioMed Central / Systematic Reviews. Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis That average, though, conceals enormous variation. A person with a small, early-stage tumor might live years, while someone diagnosed at stage IV could have only weeks.
Survival Without Treatment by Stage
Stage is the single strongest predictor of how long someone with untreated lung cancer will survive. A large analysis of U.S. cancer registry data covering hundreds of thousands of NSCLC patients found that untreated stage IV patients had a median survival of just two months, compared with about nine months for treated patients receiving chemotherapy.2Journal of Thoracic Oncology. Increasing Rates of No Treatment in Advanced-Stage Non–Small Cell Lung Cancer Patients: A Propensity-Matched Analysis For stage IIIA disease in the same dataset, untreated patients had a median survival of about six months, versus roughly sixteen and a half months for those who received chemoradiation.
Early-stage disease tells a very different story. One study of untreated stage I and II NSCLC patients, most of whom were elderly and had severe chronic lung disease preventing treatment, found a mean survival of about twelve months overall, with stage I patients averaging close to fourteen months and stage II patients averaging around eight months.3PubMed. Survival in untreated early stage non-small cell lung cancer A more recent and larger study reported even better numbers for untreated stage I NSCLC: a median survival of 45 months, with roughly 43% of untreated patients still alive at five years.4PubMed Central. Survival and outcomes after nonoperative management of operable non–small cell lung cancer That same study found untreated stage II and stage III patients had median survivals of 16 and 9 months, respectively, with five-year survival rates dropping to 17% and 14%.
Those stage I numbers may be surprising. They reflect the fact that some early-stage lung tumors grow slowly enough that a person, especially an older person with other serious health conditions, can live for years before the cancer itself becomes the dominant threat. Once the disease reaches the locally advanced or metastatic range, though, the timeline compresses sharply.
Small Cell Lung Cancer Is a Different Beast
Small cell lung cancer (SCLC) makes up about 15% of all lung cancer diagnoses and behaves much more aggressively than the non-small cell types. Without treatment, median survival after diagnosis is typically one to three months.5PMC Central. Progression-Free Survival: An Important Prognostic Marker for Long-Term Survival of Small Cell Lung Cancer SCLC tends to double in volume faster than other lung cancers. A meta-analysis of tumor growth rates found that the average doubling time for SCLC was about 73 days, compared with roughly 223 days for adenocarcinoma, the most common NSCLC subtype.6European Journal of Cancer. Lung cancer volume doubling time by computed tomography: A systematic review and meta-analysis SCLC also tends to spread early and widely. Because of this aggressive biology, SCLC is rarely caught at an early stage, and going without treatment leaves almost no runway.
For patients with SCLC who already have a very poor functional status at diagnosis, prognosis without treatment is measured in days. In one dataset, SCLC patients who were essentially bed-bound had a median survival of just seven days.7Journal of Palliative Medicine. Eastern Cooperative Oncology Group Performance Status
How Tumor Type and Growth Rate Shape the Timeline
Even within NSCLC, not all tumors grow at the same pace. The rate at which a tumor doubles in volume, called volume doubling time, varies widely by cell type and individual biology. Squamous cell carcinomas tend to grow faster than adenocarcinomas. One Japanese study found average doubling times of about 115 days for squamous cell and 222 days for adenocarcinoma.8PubMed. Tumor doubling time and prognosis in lung cancer patients: evaluation from chest films and clinical follow-up study Another study measuring doubling times with CT scans reported similar patterns, with adenocarcinoma at 305 days and squamous cell at 81 days.9Journal of Thoracic Oncology. Tumor Volume Doubling Time and Epidermal Growth Factor Receptor Mutation Status in Non-Small-Cell Lung Cancer The spread across studies is wide, but the general order holds: adenocarcinoma grows more slowly, squamous cell faster, and small cell fastest of all.
This matters for untreated survival because a slowly growing tumor takes longer to reach a size or spread to a location that becomes life-threatening. Certain molecular features also play a role. Tumors with mutations in the EGFR gene, for instance, tend to respond well to targeted therapies when treated, and the presence of that mutation is associated with different behavior even in the context of metastatic disease. One study found that patients with EGFR-mutant NSCLC who developed brain metastases had a median survival of over 25 months, compared with under four months for those without the mutation.10PubMed Central. Long-term survival of a non-small cell lung cancer patient with EGFR-mutated brain metastases: a case report That comparison involved treated patients, but it illustrates how much underlying biology can shift the trajectory.
Where the Cancer Spreads Matters Too
Once lung cancer metastasizes, the organs it reaches have a major effect on how long someone survives. Liver metastases carry the worst prognosis among common metastatic sites, with one study reporting a median survival of just three months.11Lung Cancer. Metastatic sites and survival in lung cancer Bone metastases also carry poor survival. A meta-analysis found that NSCLC patients with bone metastases had a median survival under eight months from the start of treatment, and SCLC patients with bone metastases about six months.12PubMed Central. Comprehensive Analysis of Lung Cancer Metastasis: Sites, Rates, Survival, and Risk Factors—A Systematic Review and Meta‐Analysis Brain metastases, while frightening, actually had somewhat better survival figures in the same analysis: roughly 21 months for NSCLC and about 10 months for SCLC from the point of diagnosis. Those survival figures, though, reflect treated populations. Without treatment, the timelines would be considerably shorter.
For untreated patients, metastatic disease is the leading cause of death. An autopsy study of lung cancer patients found that extensive metastatic spread was the most common immediate cause of death, accounting for about a quarter of cases. Infection, including pneumonia and sepsis, was the next most common cause, followed by complications at specific metastatic sites such as bleeding around the heart from pericardial metastases.13PubMed. Causes of death of patients with lung cancer Pulmonary hemorrhage and blood clots in the lungs also featured prominently.
Why Some People End Up Without Treatment
About one in five NSCLC patients in the United States receives no anticancer treatment at all. The proportion is higher in advanced stages, reaching about a quarter of stage IV patients.2Journal of Thoracic Oncology. Increasing Rates of No Treatment in Advanced-Stage Non–Small Cell Lung Cancer Patients: A Propensity-Matched Analysis The reasons are rarely as simple as someone refusing care out of preference. The strongest predictor of going untreated is poor physical function at the time of diagnosis. Patients who are already spending most of their day in bed or a chair are far less likely to receive treatment. One study found that a very poor functional status score was associated with a fivefold increase in the odds of treatment refusal.14PubMed Central. Risk factors associated with treatment refusal in lung cancer
Age is another major factor. Patients diagnosed at age 80 or older are significantly less likely to receive either curative or palliative treatment, even after accounting for their other health conditions and functional status.15PubMed. Who are the vulnerable lung cancer patients at risk for not receiving first-line curative or palliative treatment? Other factors include having other serious illnesses, low body weight, lower educational attainment, living alone, and even living far from a hospital.16PubMed Central. Management of patients with early stage lung cancer – why do some patients not receive treatment with curative intent? There is evidence that some elderly patients are undertreated relative to what they could tolerate. Among patients over 80 with advanced disease, the probability of receiving cancer treatment was markedly reduced, and this gap was associated with a 28% increase in mortality risk compared with younger patients after adjusting for other factors.17European Respiratory Journal. Excess mortality and undertreatment in elderly lung cancer patients: treatment nihilism in the modern era?
This matters because the survival numbers for untreated patients are partly a reflection of who those patients are. Many are very sick for reasons beyond their cancer. The untreated group is not a random sample of lung cancer patients choosing to skip therapy; it is weighted toward people who were already frail, which makes their short survival times partly a marker of overall health rather than purely a consequence of the cancer going untreated.
Performance Status and Other Prognostic Factors
If stage tells you how far the cancer has spread, performance status tells you how well the person is holding up. The standard measure used by oncologists is the ECOG scale, which runs from 0 (fully active) to 4 (completely bedridden). The gap in survival between a patient who is up and about versus one who is mostly confined to a bed or chair is enormous, whether or not treatment is given. One study of advanced NSCLC patients treated with immunotherapy found that those with a good performance status had a median survival of over 23 months, compared with about four months for those with poorer function.18JAMA Network Open. Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy Without treatment, the disparity is even starker.
Other conditions a person is living with also shape the timeline. Chronic obstructive pulmonary disease (COPD) is extremely common among lung cancer patients given their shared risk factor of smoking. Research shows that emphysema-predominant COPD roughly doubles the risk of death in lung cancer patients, even after adjusting for age, sex, smoking, and type of treatment.19PubMed Central. Impact of COPD on prognosis of lung cancer: from a perspective on disease heterogeneity On the positive side, treating the COPD itself appears to improve survival. One study found that COPD treatment in advanced NSCLC patients was associated with about a 48% reduction in the risk of death.20Scientific Reports. Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer
Age also independently predicts survival. One study found that elderly lung cancer patients had a median survival of roughly 38 weeks, compared with 57 weeks in younger patients, and a one-year survival rate of about 43% versus 67%.21PubMed Central. Age is a prognostic factor affecting survival in lung cancer patients Gender plays a role too, with women consistently showing slightly better survival than men across multiple studies.
What Living With Untreated Lung Cancer Is Like
Survival duration is only part of the picture. The quality of the time remaining matters just as much to patients and families. Lung cancer, whether treated or not, carries a heavy symptom burden. Fatigue and breathing difficulties are the most common complaints and tend to worsen steadily. Research on lung cancer patients’ quality of life shows that fatigue and respiratory problems take a particular toll on psychological well-being, while sleep disruption impairs thinking and concentration. Physical disability increases in most patients over time, and many lose the ability to fulfill their roles at home and in social life. Depression and distress are common.22PubMed Central. Quality of life of patients with lung cancer
For patients who receive only supportive care from the start, meaning comfort-focused treatment without any cancer-directed therapy, one study found a median survival of about 98 days, or a little over three months.23Nature / Scientific Reports. Decision-making factors for best supportive care alone and prognostic factors after best supportive care in non-small cell lung cancer patients Palliative radiotherapy can help with specific symptoms like pain from bone metastases, bleeding, or airway obstruction, even in patients who are not receiving curative treatment. One observational study of patients receiving urgent palliative radiotherapy for advanced lung cancer reported an overall symptom response rate of about 70%, though roughly one in five patients died within 30 days of starting that radiotherapy.24BioMed Central. Outcomes of patients receiving urgent palliative radiotherapy for advanced lung cancer: an observational study The short median time from initial consultation to death in that study, about three and a half months, underscores how late many patients present for symptom-focused care.
Even among long-term survivors who did receive treatment, the symptom picture is not rosy. A study tracking survivors over time found that about 35% experienced a significant decline in overall quality of life, driven by worsening fatigue, pain, shortness of breath, appetite loss, and coughing.25PubMed Central. Quality of Life and Symptom Burden among Long Term Lung Cancer Survivors: Changing and Adapting Among the roughly 15% whose quality of life improved, the improvement seemed to reflect adaptation to their condition rather than actual symptom relief, since their symptom burden did not objectively lessen. For patients forgoing treatment entirely, the trajectory is steeper and faster, with less access to symptom management along the way.
The Exception That Proves the Rule: Indolent Lung Cancers
Not every lung cancer is a death sentence without treatment. Screening with low-dose CT scans has revealed a small but real category of very slow-growing lung cancers that may never become life-threatening. These include certain subtypes of adenocarcinoma sometimes called adenocarcinoma in situ or minimally invasive adenocarcinoma. A study using data from the National Lung Screening Trial found that these indolent subtypes had a 100% disease-specific survival rate at seven years.26PubMed Central. Pulmonary adenocarcinoma of low malignant potential defines indolent NSCLC associated with overdiagnosis in the national lung screening trial The study estimated that about 16-17% of stage IA cancers detected by screening represented overdiagnosis, meaning cancers that would never have caused harm during the patient’s lifetime if left undiscovered.
This is an important nuance, but it comes with a serious caveat: there is currently no reliable way for an individual patient to know at the time of diagnosis whether their cancer falls into this indolent category. The 100% survival rate for these subtypes was identified retrospectively using pathology data. In clinical practice, distinguishing a slow-growing tumor that will never spread from one that has not spread yet is genuinely difficult. This is why oncologists generally recommend treatment for operable lung cancers even when they appear small and slow-growing. The risk of guessing wrong is high.
Why the Published Survival Numbers May Not Reflect Your Situation
There is a methodological wrinkle worth understanding. The systematic review that found a mean untreated survival of about seven months for NSCLC noted a significant gap depending on how the data were collected.1BioMed Central / Systematic Reviews. Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis In observational studies that followed patients from diagnosis, mean survival was about twelve months. In randomized clinical trials where untreated patients served as a control group, it was about five months. The difference likely reflects the fact that trial participants tend to have more advanced disease and are enrolled specifically because their cancer is progressing, while observational studies capture a broader mix including early-stage patients who were never treated for other medical reasons.
Lead-time bias also complicates how screening-detected cancers affect the numbers. If a cancer is found through screening two years before it would have caused symptoms, that patient’s survival from diagnosis will look two years longer, even if they die on the exact same day they would have without screening. Research has found that for early-stage lung cancer, this lead-time effect can be on the order of eleven months, meaning survival statistics for screening-detected cases will look better than they truly are by close to a year.27PubMed Central. Estimating lead-time bias in lung cancer diagnosis of patients with previous cancers For advanced-stage disease, the lead-time effect shrinks to nearly nothing. One study estimating the impact of lead-time bias on screening effectiveness found that failure to account for it could overestimate the benefit of screening by roughly 38%.28PubMed Central. Considering lead-time bias in evaluating the effectiveness of lung cancer screening with real-world data
The practical upshot: when you read a survival statistic for untreated lung cancer, it applies to a population, not to an individual. Your age, overall fitness, tumor type, stage, molecular features, and other health conditions all push the number in different directions. A fit 65-year-old with a small, slow-growing adenocarcinoma and a frail 80-year-old with widespread small cell lung cancer are living in entirely different worlds, even though both technically have “untreated lung cancer.”
Palliative Care Without Chemotherapy Is Still Care
Choosing not to pursue cancer-directed treatment does not mean choosing to do nothing. Palliative care focuses on managing pain, breathing difficulties, nausea, anxiety, and other symptoms. It can involve medications, oxygen therapy, drainage of fluid around the lungs, nerve blocks for pain, and psychological support. For patients whose cancer is advanced and whose overall health makes aggressive treatment unlikely to help, palliative care can meaningfully improve the quality of whatever time remains.
The distinction between “no treatment” and “best supportive care” matters when interpreting the research. In many studies, the “untreated” group received no cancer-directed therapy but did receive supportive care. A patient who is truly receiving no medical attention at all is likely to have worse outcomes than even the untreated groups in these studies. The study that found about three months of median survival with supportive care alone also found that being male, having a low body mass index, having poor lung function, and having a poor performance status were all associated with shorter survival within that group.23Nature / Scientific Reports. Decision-making factors for best supportive care alone and prognostic factors after best supportive care in non-small cell lung cancer patients Even within the population that forgoes chemotherapy, outcomes are not uniform.
If you or someone you know is facing a lung cancer diagnosis and considering whether to pursue treatment, the conversation with an oncologist is worth having even if the ultimate decision is to decline. Understanding the specific tumor type, stage, molecular profile, and how those factors interact with your overall health gives you the clearest possible picture. The population-level statistics described here set the range, but they cannot tell you where you fall within it.